GlassScriptPhysician profile
Brigitte R Torres
NPI 1225793938
$1,650.43
in general payments reported to CMS, 2019-2025
23 companies · $822 in 2025
The $822 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $250 · 2024: $579 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,650.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.43 | 2023-2025 | Jardiance, Synjardy |
| Abbvie INC. | $166.56 | 2025 | |
| Pfizer INC. | $164.84 | 2023-2025 | |
| Lilly USA, LLC | $162.41 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $143.47 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lundbeck LLC | $109.56 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $84.80 | 2025 | Sunosi, Symbravo |
| Abbott Laboratories | $83.31 | 2024-2025 | Freestyle Libre |
| Biogen, INC. | $70.02 | 2025 | Vumerity, Leqembi |
| Bayer Healthcare Pharmaceuticals INC. | $60.04 | 2023-2025 | |
| Novo Nordisk INC | $55.97 | 2023-2025 | Ozempic, Rybelsus |
| Argenx US, INC. | $42.48 | 2025 | Vyvgart Hytrulo |
| Amgen INC. | $38.23 | 2024-2025 | Uplizna, Repatha |
| Mylan Specialty L.P. | $32.23 | 2023 | Yupelri |
| Philips North America LLC | $26.86 | 2025 | Home Pi Undivided |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $26.24 | 2025 | |
| Sk Life Science, INC. | $25.64 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $25.01 | 2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $23.40 | 2025 | |
| Sumitomo Pharma America, INC. | $17.03 | 2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $15.83 | 2024 | Gvoke Hypopen |
| Genentech USA, INC. | $15.19 | 2025 | Ocrevus Zunovo |
| Ucb, INC. | $14.88 | 2024 | Nayzilam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brigitte Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.